AR078290A1 - Composicion farmaceutica. funcion del acido n-2-hidroxi-etil-piperazin-n`-2- etanosulfonico (hepes) en el control del dolor y en la prevencion de lesiones desmielinizantes. metodo para tratar dolor. - Google Patents
Composicion farmaceutica. funcion del acido n-2-hidroxi-etil-piperazin-n`-2- etanosulfonico (hepes) en el control del dolor y en la prevencion de lesiones desmielinizantes. metodo para tratar dolor.Info
- Publication number
- AR078290A1 AR078290A1 ARP100103407A ARP100103407A AR078290A1 AR 078290 A1 AR078290 A1 AR 078290A1 AR P100103407 A ARP100103407 A AR P100103407A AR P100103407 A ARP100103407 A AR P100103407A AR 078290 A1 AR078290 A1 AR 078290A1
- Authority
- AR
- Argentina
- Prior art keywords
- hepes
- hydroxy
- pharmaceutical composition
- acid
- agents
- Prior art date
Links
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 title abstract 5
- 239000007995 HEPES buffer Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000006378 damage Effects 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 4
- 208000016192 Demyelinating disease Diseases 0.000 abstract 3
- 239000004606 Fillers/Extenders Substances 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 3
- 239000007853 buffer solution Substances 0.000 abstract 3
- 239000003086 colorant Substances 0.000 abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 239000003755 preservative agent Substances 0.000 abstract 3
- 239000008223 sterile water Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 2
- 239000000935 antidepressant agent Substances 0.000 abstract 2
- 229940005513 antidepressants Drugs 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 229940076279 serotonin Drugs 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24346409P | 2009-09-17 | 2009-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078290A1 true AR078290A1 (es) | 2011-10-26 |
Family
ID=43757159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103407A AR078290A1 (es) | 2009-09-17 | 2010-09-17 | Composicion farmaceutica. funcion del acido n-2-hidroxi-etil-piperazin-n`-2- etanosulfonico (hepes) en el control del dolor y en la prevencion de lesiones desmielinizantes. metodo para tratar dolor. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8883855B2 (OSRAM) |
| EP (3) | EP2477626A4 (OSRAM) |
| JP (4) | JP2013505264A (OSRAM) |
| KR (1) | KR101737775B1 (OSRAM) |
| CN (4) | CN103977405A (OSRAM) |
| AR (1) | AR078290A1 (OSRAM) |
| AU (1) | AU2010295445B2 (OSRAM) |
| BR (1) | BR112012006155A2 (OSRAM) |
| CA (3) | CA2774375C (OSRAM) |
| HK (1) | HK1199621A1 (OSRAM) |
| IL (2) | IL264055B2 (OSRAM) |
| IN (1) | IN2012DN02499A (OSRAM) |
| MX (2) | MX360190B (OSRAM) |
| MY (2) | MY159626A (OSRAM) |
| NZ (1) | NZ598861A (OSRAM) |
| SG (3) | SG179191A1 (OSRAM) |
| TW (2) | TWI562777B (OSRAM) |
| WO (1) | WO2011035212A2 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213425B2 (en) | 2009-09-17 | 2019-02-26 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2851678T3 (es) | 2014-07-21 | 2021-09-08 | Glia Llc | Método para el tratamiento de deterioro cognitivo o emocional asociado con la radioterapia y quimioterapia con cannabinoides |
| CA2984379C (en) * | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ATE207074T1 (de) | 1995-07-06 | 2001-11-15 | Fraunhofer Ges Forschung | Thiolsilane, verfahren zu deren herstellung und deren verwendung |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| ES2392391T3 (es) * | 1998-02-11 | 2012-12-10 | Bhi Limited Partnership | Método para modular la activación de macrófagos |
| CA2585983C (en) | 2004-11-10 | 2014-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| EP2011491A1 (en) | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
| EP2167068A2 (en) * | 2007-07-05 | 2010-03-31 | Inserm-Institut National De La Sante Et De La Recherche Medicale | Anticonvulsive pharmaceutical compositions |
| EP2163246A1 (en) * | 2008-09-12 | 2010-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
| JP2013504151A (ja) | 2009-09-04 | 2013-02-04 | ビーエーエスエフ ソシエタス・ヨーロピア | 色素増感太陽電池 |
| CN103977405A (zh) | 2009-09-17 | 2014-08-13 | 北德克萨斯医学联合会 | N-2-羟基-乙基-哌嗪-n’-2-乙磺酸（hepes）在疼痛控制和脱髓鞘损伤逆转中的作用 |
| AU2014206220B2 (en) | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
-
2010
- 2010-09-17 CN CN201410166019.3A patent/CN103977405A/zh active Pending
- 2010-09-17 AR ARP100103407A patent/AR078290A1/es unknown
- 2010-09-17 MX MX2015008916A patent/MX360190B/es unknown
- 2010-09-17 US US12/885,404 patent/US8883855B2/en active Active
- 2010-09-17 IL IL264055A patent/IL264055B2/en unknown
- 2010-09-17 CA CA2774375A patent/CA2774375C/en active Active
- 2010-09-17 EP EP10817952.4A patent/EP2477626A4/en not_active Withdrawn
- 2010-09-17 EP EP19161338.9A patent/EP3520794A3/en active Pending
- 2010-09-17 SG SG2012018842A patent/SG179191A1/en unknown
- 2010-09-17 CN CN201811365002.5A patent/CN109224077A/zh active Pending
- 2010-09-17 KR KR1020127009683A patent/KR101737775B1/ko active Active
- 2010-09-17 MY MYPI2012001195A patent/MY159626A/en unknown
- 2010-09-17 MX MX2012003212A patent/MX2012003212A/es active IP Right Grant
- 2010-09-17 JP JP2012529955A patent/JP2013505264A/ja active Pending
- 2010-09-17 TW TW103124615A patent/TWI562777B/zh active
- 2010-09-17 AU AU2010295445A patent/AU2010295445B2/en active Active
- 2010-09-17 CA CA3122553A patent/CA3122553A1/en active Pending
- 2010-09-17 CN CN201710494640.6A patent/CN107260740A/zh active Pending
- 2010-09-17 MY MYPI2015002505A patent/MY174012A/en unknown
- 2010-09-17 CA CA2977918A patent/CA2977918C/en active Active
- 2010-09-17 BR BR112012006155A patent/BR112012006155A2/pt not_active Application Discontinuation
- 2010-09-17 CN CN2010800521032A patent/CN102612366A/zh active Pending
- 2010-09-17 TW TW099131755A patent/TWI494106B/zh active
- 2010-09-17 SG SG10201500510YA patent/SG10201500510YA/en unknown
- 2010-09-17 NZ NZ598861A patent/NZ598861A/xx unknown
- 2010-09-17 SG SG10202100421XA patent/SG10202100421XA/en unknown
- 2010-09-17 EP EP14191925.8A patent/EP2835133B1/en active Active
- 2010-09-17 WO PCT/US2010/049405 patent/WO2011035212A2/en not_active Ceased
-
2012
- 2012-03-15 IL IL218677A patent/IL218677B/en active IP Right Grant
- 2012-03-22 IN IN2499DEN2012 patent/IN2012DN02499A/en unknown
-
2014
- 2014-09-09 US US14/481,582 patent/US9867820B2/en active Active
- 2014-11-14 JP JP2014231168A patent/JP5974062B2/ja active Active
-
2015
- 2015-01-06 HK HK15100074.2A patent/HK1199621A1/xx unknown
- 2015-02-10 JP JP2015024177A patent/JP2015129150A/ja active Pending
-
2016
- 2016-07-15 JP JP2016140167A patent/JP6347807B2/ja active Active
-
2017
- 2017-10-04 US US15/725,007 patent/US10213425B2/en active Active
-
2019
- 2019-01-14 US US16/247,233 patent/US20190142825A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213425B2 (en) | 2009-09-17 | 2019-02-26 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| MX364378B (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| BR112014012054A2 (pt) | métodos de tratamento com deferiprona | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| BR112016029437A2 (pt) | métodos para tratamento e prevenção de doenças de instabilidade vascular | |
| AR078290A1 (es) | Composicion farmaceutica. funcion del acido n-2-hidroxi-etil-piperazin-n`-2- etanosulfonico (hepes) en el control del dolor y en la prevencion de lesiones desmielinizantes. metodo para tratar dolor. | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MY163107A (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| RU2557949C1 (ru) | Способ лечения лучевого и интерстициального цистита | |
| Sharma et al. | Differential Effect of Paromomycin and Nitazoxanide on Clinical Isolates of Cryptosporidia In Vitro. | |
| UA56015U (ru) | Применение производных глюкозамина в качестве церебропротекторного средства | |
| BR112015009936A2 (pt) | método para tratar disfunção sexual feminina em uma paciente do sexo feminino diagnosticada com disfunção sexual feminina, mas desejando ter atividade sexual; uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada | |
| Vedanayagam | Hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |